Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
Acta Pharmacol Sin ; 2024 Jun 20.
Article in English | MEDLINE | ID: mdl-38902501

ABSTRACT

The impairment of blood-brain barrier (BBB) integrity is the pathological basis of hemorrhage transformation and vasogenic edema following thrombolysis and endovascular therapy. There is no approved drug in the clinic to reduce BBB damage after acute ischemic stroke (AIS). Glial growth factor 2 (GGF2), a recombinant version of neuregulin-1ß that can stimulates glial cell proliferation and differentiation, has been shown to alleviate free radical release from activated microglial cells. We previously found that activated microglia and proinflammatory factors could disrupt BBB after AIS. In this study we investigated the effects of GGF2 on AIS-induced BBB damage as well as the underlying mechanisms. Mouse middle cerebral artery occlusion model was established: mice received a 90-min ischemia and 22.5 h reperfusion (I/R), and were treated with GGF2 (2.5, 12.5, 50 ng/kg, i.v.) before the reperfusion. We showed that GGF2 treatment dose-dependently decreased I/R-induced BBB damage detected by Evans blue (EB) and immunoglobulin G (IgG) leakage, and tight junction protein occludin degradation. In addition, we found that GGF2 dose-dependently reversed AIS-induced upregulation of vesicular transcytosis increase, caveolin-1 (Cav-1) as well as downregulation of major facilitator superfamily domain containing 2a (Mfsd2a). Moreover, GGF2 decreased I/R-induced upregulation of PDZ and LIM domain protein 5 (Pdlim5), an adaptor protein that played an important role in BBB damage after AIS. In addition, GGF2 significantly alleviated I/R-induced reduction of YAP and TAZ, microglial cell activation and upregulation of inflammatory factors. Together, these results demonstrate that GGF2 treatment alleviates the I/R-compromised integrity of BBB by inhibiting Mfsd2a/Cav-1-mediated transcellular permeability and Pdlim5/YAP/TAZ-mediated paracellular permeability.

2.
Molecules ; 29(11)2024 May 30.
Article in English | MEDLINE | ID: mdl-38893450

ABSTRACT

Isoflavones are a class of natural products that exhibit a wide range of interesting biological properties, including antioxidant, hepatoprotective, antimicrobial, and anti-inflammatory activities. Scandenone (1), osajin (2), and 6,8-diprenylgenistein (3) are natural prenylated isoflavones that share the same polyphenol framework. In this research, the key intermediate 15 was used for the synthesis of the natural isoflavones 1-3, establishing a stereoselective synthetic method for both linear and angular pyran isoflavones. The antibacterial activities of 1-3 were also evaluated, and all of them displayed good antibacterial activity against Gram-positive bacteria. Among them, 2 was the most potent one against MRSA, with a MIC value of 2 µg/mL, and the SEM assay indicated that the bacterial cell membranes of both MRSA and E. faecalis could be disrupted by 2. These findings suggest that this type of isoflavone could serve as a lead for the development of novel antibacterial agents for the treatment of Gram-positive bacterial infections.


Subject(s)
Anti-Bacterial Agents , Isoflavones , Microbial Sensitivity Tests , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Isoflavones/pharmacology , Isoflavones/chemistry , Isoflavones/chemical synthesis , Molecular Structure , Methicillin-Resistant Staphylococcus aureus/drug effects , Gram-Positive Bacteria/drug effects , Biological Products/pharmacology , Biological Products/chemistry , Biological Products/chemical synthesis , Enterococcus faecalis/drug effects
3.
Chembiochem ; 24(20): e202300395, 2023 10 17.
Article in English | MEDLINE | ID: mdl-37485551

ABSTRACT

ß-Carboline alkaloids have a variety of pharmacological activities, such as antitumor, antibiosis and antidiabetes. Harmine and harmol are two structurally similar ß-carbolines that occur in many medicinal plants. In this work, we chose harmine and harmol to impede the amyloid fibril formation of human islet amyloid polypeptide (hIAPP) associated with type 2 diabetes mellitus (T2DM), by a series of physicochemical and biochemical methods. The results indicate that harmine and harmol effectively prevent peptide fibril formation and alleviate toxic oligomer species. In addition, both small molecules exhibit strong binding affinities with hIAPP mainly through hydrophobic and hydrogen bonding interactions, thus reducing the cytotoxicity induced by hIAPP. Their distinct binding pattern with hIAPP is closely linked to the molecular configuration of the two small molecules, affecting their ability to impede peptide aggregation. The study is of great significance for the application and development of ß-carboline alkaloids against T2DM.


Subject(s)
Diabetes Mellitus, Type 2 , Humans , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/pathology , Islet Amyloid Polypeptide/chemistry , Harmine , Amyloid/chemistry
4.
Neurochem Res ; 47(2): 503-515, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34661796

ABSTRACT

Recent evidence has shown that demyelination occurs along with axonal degeneration in spinal cord injury (SCI) during the secondary injury phase. Oligodendrocyte precursor cells (OPC) are present in the lesions but fail to differentiate into mature oligodendrocytes and form new myelin. Given the limited recovery of neuronal functions after SCI in adults without effective treatment available so far, it remains unknown whether enhancing OPC differentiation and myelination could benefit the recovery of SCI. To show the significance of myelin regeneration after SCI, the injury was treated with clemastine in the rat model. Clemastine is an FDA-approved drug that is potent in promoting oligodendrocyte differentiation and myelination in vivo, for four weeks following SCI. Motor function was assessed using sloping boards and grid walking tests and scored according to the Basso, Beattie, and Bresnahan protocol. The myelin integrity and protein expression were evaluated using transmission electron microscopy and immunofluorescence, respectively. The results indicated that clemastine treatment preserves myelin integrity, decreases loss of axons and improves functional recovery in the rat SCI model. The presented data suggest that myelination-enhancing strategies may serve as a potential therapeutic approach for the functional recovery in SCI.


Subject(s)
Clemastine , Spinal Cord Injuries , Animals , Clemastine/metabolism , Clemastine/pharmacology , Clemastine/therapeutic use , Myelin Sheath/metabolism , Oligodendroglia/metabolism , Rats , Recovery of Function , Spinal Cord/metabolism , Spinal Cord Injuries/pathology
5.
Phys Chem Chem Phys ; 23(25): 13785-13788, 2021 Jun 30.
Article in English | MEDLINE | ID: mdl-34159986

ABSTRACT

Herein, the phase behaviors of both bulk and confined deep eutectic solvents in controlled pore glasses were first investigated. Glass transition, cold crystallization and melting behaviors alter significantly in the nanopores due to the size effect and interfacial interactions. Kinetic analysis of the crystallization reveals increased effective activation energies and pre-exponential factors under nanoconfinement.

6.
J Nat Prod ; 84(11): 2866-2874, 2021 11 26.
Article in English | MEDLINE | ID: mdl-34658231

ABSTRACT

Syringin (1), a natural bioactive glucoside isolated from the root of Acanthopanax senticosus (Rupr. Maxim.) Harms, possesses significant anti-inflammatory activity. In this study, we have accomplished the total syntheses of syringin (1), along with its natural analogues 2-12, from a common starting material, syringaldehyde (13), in 4-8 steps with an overall yields of 11.8-61.3%. The anti-inflammatory activities of these compounds were determined against NO production in the LPS-stimulated RAW264.7 cells. Among them, compounds 1-5, 7, and 9 exhibited different levels of anti-inflammatory activity.


Subject(s)
Anti-Inflammatory Agents/chemical synthesis , Glucosides/chemical synthesis , Phenylpropionates/chemical synthesis , Animals , Anti-Inflammatory Agents/pharmacology , Glucosides/pharmacology , Lipopolysaccharides/pharmacology , Mice , Nitric Oxide/biosynthesis , Phenylpropionates/pharmacology , RAW 264.7 Cells
7.
J Asian Nat Prod Res ; 23(3): 284-293, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32079415

ABSTRACT

Phenethyl glycosides having phenolic or methoxy functions at benzene rings are substances widely occurring in nature. This kind of compounds has been shown to have anti-oxidant, anti-inflammatory, and anticancer activities. However, some of them are not naturally abundant, thus the synthesis of such molecules is desirable. In this paper, natural phenethyl glycosides 3 and 4 were first totally synthesized from easily available materials with overall yields of 50.5% and 40.1%, respectively. And a new synthetic route to obtain natural phenethyl glycoside 2 in 46.2% yield was also described.


Subject(s)
Glycosides , Phenols , Anti-Inflammatory Agents , Molecular Structure
8.
J Biol Inorg Chem ; 24(2): 179-189, 2019 03.
Article in English | MEDLINE | ID: mdl-30701360

ABSTRACT

The abnormal aggregation and deposition of human islet amyloid polypeptide (hIAPP) are implicated in the pathogeny of type 2 diabetes mellitus (T2DM). Many aromatic ring-containing Ru complexes inhibit the aggregation of hIAPP. A new Ru complex Ru(bipy)(met)2·3H2O (1), where bipy is 2,2'-bipyridine and met is methionine, was synthesized and employed to resist the fibril formation of hIAPP and to promote the biocompatibility of metal complexes. Two polypyridyl Ru complexes, namely [Ru(bipy)3]Cl2(2) and Ru(bipy)2Cl2(3), were used for comparison. Results reveal that the three Ru complexes can inhibit hIAPP aggregation and depolymerize mature hIAPP fibrils. Interaction studies show that Ru complexes bind to hIAPP through metal coordination, hydrophobic interaction, and other intermolecular forces. The binding of the three compounds is spontaneous and exothermic. The compounds also rescue peptide-induced cytotoxicity to some extent. Similar to 3, the novel methionine-Ru complex 1 exhibits an enhanced inhibitory effect and binding affinity to hIAPP possibly because of the smaller steric hindrance and more profitable molecular configuration of 1 than those of 2. The newly designed amino acid-Ru complex may provide new insights into the treatment of T2DM and related amyloidosis diseases. Methionine-Ru complex effectively impedes the fibril formation of human islet amyloid polypeptide.


Subject(s)
Coordination Complexes/pharmacology , Islet Amyloid Polypeptide/antagonists & inhibitors , Methionine/pharmacology , Ruthenium/pharmacology , Animals , Cells, Cultured , Coordination Complexes/chemical synthesis , Coordination Complexes/chemistry , Humans , Islet Amyloid Polypeptide/metabolism , Methionine/chemistry , Molecular Structure , Particle Size , Rats , Ruthenium/chemistry , Surface Properties
9.
J Biol Inorg Chem ; 22(7): 1065-1074, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28801867

ABSTRACT

The aggregation of human islet amyloid polypeptide (hIAPP) is associated with type II diabetes. The misfolding of hIAPP induces amyloid deposition and causes ß-cell dysfunction. Metal complexes are potential metallodrugs that may reverse the aggregation of amyloid peptides. hIAPP19-37 is a crucial fragment of the full-length hIAPP1-37 and contains typical aromatic residues and a core hydrophobic region. In this work, we studied the effects of titanocene complexes titanocene dichloride (1), titanocene salicylic acid complex (2), and titanocene methionine complex (3) on the aggregation behavior of hIAPP19-37. We also explored the possible interactions of these complexes with hIAPP19-37. Results demonstrated that the titanocene complexes could effectively inhibit the aggregation of hIAPP19-37. The complexes bound with hIAPP19-37 in a spontaneous and exothermic process through hydrophobic interaction. Moreover, complex 3 could significantly decrease the cytotoxicity of hIAPP19-37 and improve cell survival. These data provide a basis for the use of titanocene complexes as potential agents against amyloidosis.


Subject(s)
Islet Amyloid Polypeptide/metabolism , Organometallic Compounds/chemistry , Organometallic Compounds/pharmacology , Protein Aggregates/drug effects , Protein Aggregation, Pathological/drug therapy , Animals , Cell Line , Cell Survival/drug effects , Humans , Islet Amyloid Polypeptide/chemistry , Peptides/chemistry , Peptides/metabolism , Protein Aggregation, Pathological/pathology , Rats , Thermodynamics , Titanium/chemistry , Titanium/pharmacology
10.
J Biol Inorg Chem ; 21(2): 251-61, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26841790

ABSTRACT

Cytoglobin (Cgb) is a member of hemoprotein family with roles in NO metabolism, fibrosis, and tumourigenesis. Similar to other hemoproteins, Cgb structure and functions are markedly influenced by distal key residues. The sixth ligand His(81) (E7) is crucial to exogenous ligand binding, heme pocket conformation, and physiological roles of this protein. However, the effects of other key residues on heme pocket and protein biological functions are not well known. In this work, a molecular dynamics (MD) simulation study of two single mutants in CO-ligated Cgb (L46FCgbCO and L46VCgbCO) and two double mutants (L46FH81QCgbCO and L46VH81QCgbCO) was conducted to explore the effects of the key distal residues Leu(46)(B10) and His(81)(E7) on Cgb structure and functions. Results indicated that the distal mutation of B10 and E7 affected CgbCO dynamic properties on loop region fluctuation, internal cavity rearrangement, and heme motion. The distal conformation change was reflected by the distal key residues Gln(62) (CD3) and Arg(84)(E10). The hydrogen bond between heme propionates with CD3 or E10 residues were evidently influenced by B10/E7 mutation. Furthermore, heme pocket rearrangement was also observed based on the distal pocket volume and occurrence rate of inner cavities. The mutual effects of B10 and E7 residues on protein conformational rearrangement and other dynamic features were expressed in current MD studies of CgbCO and its distal mutants, suggesting their crucial role in heme pocket stabilization, ligand binding, and Cgb biological functions. The mutation of distal B10 and E7 residues affects the dynamic features of carboxy cytoglobin.


Subject(s)
Globins/chemistry , Molecular Dynamics Simulation , Mutation , Cytoglobin , Globins/genetics
11.
Mar Drugs ; 13(6): 3259-75, 2015 May 27.
Article in English | MEDLINE | ID: mdl-26023835

ABSTRACT

In the present study, we synthesized and, structurally and functionally characterized a novel α4/7-conotoxin Mr1.7 (PECCTHPACHVSHPELC-NH2), which was previously identified by cDNA libraries from Conus marmoreus in our lab. The NMR solution structure showed that Mr1.7 contained a 310-helix from residues Pro7 to His10 and a type I ß-turn from residues Pro14 to Cys17. Electrophysiological results showed that Mr1.7 selectively inhibited the α3ß2, α9α10 and α6/α3ß2ß3 neuronal nicotinic acetylcholine receptors (nAChRs) with an IC50 of 53.1 nM, 185.7 nM and 284.2 nM, respectively, but showed no inhibitory activity on other nAChR subtypes. Further structure-activity studies of Mr1.7 demonstrated that the PE residues at the N-terminal sequence of Mr1.7 were important for modulating its selectivity, and the replacement of Glu2 by Ala resulted in a significant increase in potency and selectivity to the α3ß2 nAChR. Furthermore, the substitution of Ser12 with Asn in the loop2 significantly increased the binding of Mr1.7 to α3ß2, α3ß4, α2ß4 and α7 nAChR subtypes. Taken together, this work expanded our knowledge of selectivity and provided a new way to improve the potency and selectivity of inhibitors for nAChR subtypes.


Subject(s)
Conotoxins/pharmacology , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/drug effects , Animals , Conotoxins/administration & dosage , Conotoxins/chemistry , Conus Snail/chemistry , Inhibitory Concentration 50 , Magnetic Resonance Spectroscopy , Nicotinic Antagonists/administration & dosage , Nicotinic Antagonists/chemistry , Receptors, Nicotinic/metabolism , Structure-Activity Relationship
12.
Inorg Chem ; 53(10): 5044-54, 2014 May 19.
Article in English | MEDLINE | ID: mdl-24787240

ABSTRACT

Prion diseases belong to a group of infectious, fatal neurodegenerative disorders. The conformational conversion of a cellular prion protein (PrP(C)) into an abnormal misfolded isoform (PrP(Sc)) is the key event in prion disease pathology. PrP106-126 resembles PrP(Sc) in some physicochemical and biological characteristics, such as apoptosis induction in neurons, fibrillar formation, and mediation of the conversion of native cellular PrP(C) to PrP(Sc). Numerous studies have been conducted to explore the inhibiting methods on the aggregation and neurotoxicity of prion neuropeptide PrP106-126. We showed that PrP106-126 aggregation, as assessed by fluorescence assay and atomic force microscopy, is inhibited by platinum complexes cisplatin, carboplatin, and Pt(bpy)Cl2. ESI-MS and NMR assessments of PrP106-126 and its mutant peptides demonstrate that platinum complexes bind to the peptides in coordination and nonbonded interactions, which rely on the ligand properties and the peptide sequence. In peptides, methionine residue is preferred as a potent binding site over histidine residue for the studied platinum complexes, implying a typical thiophile characteristic of platinum. The neurotoxicity induced by PrP106-126 is better inhibited by Pt(bpy)Cl2 and cisplatin. Furthermore, the ligand configuration contributes to both the binding affinity and the inhibition of peptide aggregation. The pursuit of novel platinum candidates that selectively target prion neuropeptide is noteworthy for medicinal inorganic chemistry and chemical biology.


Subject(s)
Carboplatin/pharmacology , Cisplatin/pharmacology , Organoplatinum Compounds/pharmacology , Prions/antagonists & inhibitors , Protein Aggregates/drug effects , Carboplatin/chemical synthesis , Carboplatin/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Cisplatin/chemical synthesis , Cisplatin/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Organoplatinum Compounds/chemical synthesis , Organoplatinum Compounds/chemistry , Prions/metabolism , Structure-Activity Relationship
13.
ACS Chem Neurosci ; 15(2): 245-257, 2024 01 17.
Article in English | MEDLINE | ID: mdl-38133816

ABSTRACT

Development of potential inhibitors to prevent prion protein (PrP) fibrillation is a therapeutic strategy for prion diseases. The prion neuropeptide PrP106-126, a research model of abnormal PrP (PrPSc), presents similar physicochemical and biochemical characters to PrPSc, which is also a target of potential inhibitors against prion deposition. Many flavones have antioxidant, anti-inflammatory, and antibacterial properties, and they are applied in treating prion disorder and other amyloidosis as well. However, the inhibition mechanism of flavones on PrP106-126 fibrillation is still unclear. In the current work, apigenin and nepetin were used to suppress the aggregation of PrP106-126 and to alleviate the peptide-induced cytotoxicity. The results showed that apigenin and nepetin impeded the fibril formation of PrP106-126 and depolymerized the preformed fibrils. They were bound to PrP106-126 predominantly by hydrophobic and hydrogen bonding interactions. In addition, both flavones upregulated cell viability and decreased membrane leakage through reducing peptide oligomerization. The differences in inhibition and cell protection between the two small molecules were presumably attributed to the substitution of hydroxyl and methoxy groups in nepetin, which demonstrated the significant structure-function relationship of flavones with prion neuropeptide and the prospect of flavonoids as drug candidates against prion diseases.


Subject(s)
Flavones , Neuropeptides , Prion Diseases , Prions , Humans , Prions/metabolism , Apigenin/pharmacology , Peptide Fragments/metabolism , Prion Diseases/metabolism , Peptides
14.
Biomed Pharmacother ; 179: 117337, 2024 Aug 26.
Article in English | MEDLINE | ID: mdl-39191022

ABSTRACT

Increased blood-brain barrier (BBB) permeability can lead to cerebral vasogenic edema and hemorrhagic transformation (HT) after reperfusion with tissue plasminogen activator (tPA), the only United States Food and Drug Administration (FDA)-approved treatment for acute ischemia stroke (AIS). The therapeutic benefits of tPA after AIS are partially outweighed by a more than a six-fold increase in the risk of symptomatic intracerebral hemorrhage. Therefore, strategies to protect the integrity of BBB are urgently needed to reduce HT and vasogenic edema after tPA thrombolysis or endovascular thrombectomy. Interestingly, an NIH study showed that smokers treated with tPA had a significantly lower prevalence of brain hemorrhage than nonsmokers, suggesting that cigarette smoking may protect patients treated with tPA from the side effects of cerebral hemorrhage. Importantly, we recently showed that treatment with nicotine reduces AIS-induced BBB damage and that modulating α7nAChR by modulation could reduce ischemia/reperfusion-induced BBB damage, suggesting that α7nAChR could be a potential target to reduce BBB after AIS. In this review, we first provide an overview of stroke and the impact of α7nAChR activation on BBB damage. Next, we discuss the features and mechanism of BBB destruction after AIS. We then discuss the effect of nicotine effect on BBB integrity as well as the mechanism underlying those effects. Finally, we discuss the side effects and potential strategies for modulating α7nAChR to reduce AIS-induced BBB damage.

15.
Neurochem Int ; 177: 105744, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38663454

ABSTRACT

Traumatic brain injury (TBI) often results in persistent neurological dysfunction, which is closely associated with white matter injury. The mechanisms underlying white matter injury after TBI remain unclear. Ferritinophagy is a selective autophagic process that degrades ferritin and releases free iron, which may cause ferroptosis. Although ferroptosis has been demonstrated to be involved in TBI, it is unclear whether ferritinophagy triggers ferroptosis in TBI. Integrated stress response inhibitor (ISRIB) has neuroprotective properties. However, the effect of ISRIB on white matter after TBI remains uncertain. We aimed to investigate whether ferritinophagy was involved in white matter injury following TBI and whether ISRIB can mitigate white matter injury after TBI by inhibiting ferritinophagy. In this study, controlled cortical impact (CCI) was performed on rats to establish the TBI model. Ferritinophagy was measured by assessing the levels of nuclear receptor coactivator 4 (NCOA4), which regulates ferritinophagy, ferritin heavy chain 1(FTH1), LC3, ATG5, and FTH1 colocalization with LC3 in the white matter. Increased NCOA4 and decreased FTH1 were detected in our study. FTH1 colocalization with LC3 enhanced in the white matter after TBI, indicating that ferritinophagy was activated. Immunofluorescence co-localization results also suggested that ferritinophagy occurred in neurons and oligodendrocytes after TBI. Furthermore, ferroptosis was assessed by determining free iron content, MDA content, GSH content, and Perl's staining. The results showed that ferroptosis was suppressed by NCOA4 knockdown via shNCOA4 lentivirus infection, indicating that ferroptosis in TBI is triggered by ferritinophagy. Besides, NCOA4 deletion notably improved white matter injury following TBI, implying that ferritinophagy contributed to white matter injury. ISRIB treatment reduced the occurrence of ferritinophagy in neurons and oligodendrocytes, attenuated ferritinophagy-induced ferroptosis, and alleviated white matter injury. These findings suggest that NCOA4-mediated ferritinophagy is a critical mechanism underlying white matter injury after TBI. ISRIB holds promise as a therapeutic agent for this condition.


Subject(s)
Brain Injuries, Traumatic , Ferritins , Nuclear Receptor Coactivators , Rats, Sprague-Dawley , White Matter , Animals , Brain Injuries, Traumatic/metabolism , Brain Injuries, Traumatic/pathology , White Matter/metabolism , White Matter/pathology , White Matter/drug effects , Nuclear Receptor Coactivators/metabolism , Nuclear Receptor Coactivators/genetics , Ferritins/metabolism , Male , Rats , Ferroptosis/drug effects , Ferroptosis/physiology , Autophagy/drug effects , Autophagy/physiology , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use
16.
J Biol Inorg Chem ; 18(8): 947-55, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24037220

ABSTRACT

Cytoglobin (Cgb) is a hexacoordinate globin that plays various physiological roles, including O2 transport, enzyme activity, and lipid peroxidation. The distal His(81)(E7) residue acts as the native sixth ligand and is crucial to exogenous ligand binding, distal environment adjustment, and heme pocket stabilization. The role of E7 has been widely studied in myoglobin, neuroglobin, and hemoglobin, but not in Cgb. In this work, the structural dynamic features of CO-ligated Cgb, CgbCO, as well as its three distal mutants H81QCgbCO, H81LCgbCO, and H81VCgbCO, were examined by performing molecular dynamics (MD) simulations. Results revealed that distal mutation significantly affected the dynamic properties of the CD-D-E and EF loop regions of Cgb. Distinct fluctuations and the occurrence of new inner cavities reflected rearrangements of the heme pocket. Distal mutation was found to affect heme motion slightly, indicating a different heme motion mechanism than that for neuroglobin. Some key residues such as E7 and CD3 showed remarkable changes in their dynamics that contributed to heme pocket rearrangement and loop region fluctuations. MD studies of four CgbCO models indicated that the distal E7 residue was a crucial influence on the dynamics of CgbCO in terms of loop fluctuations, cavity rearrangement, and slight heme motion.


Subject(s)
Carbon Monoxide/metabolism , Globins/chemistry , Globins/genetics , Point Mutation , Binding Sites , Cytoglobin , Globins/metabolism , Humans , Molecular Dynamics Simulation , Protein Conformation
17.
J Biol Inorg Chem ; 18(7): 767-78, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23982344

ABSTRACT

Prion diseases are characterized by conformational conversion of prion protein from a normal cellular form to an abnormal scrapie isoform (PrP(Sc)). PrP106-126 is a prion neuropeptide and an accepted model used to study the characteristics of PrP(Sc) because such a model has biological and physiochemical properties similar to those of PrP(Sc). Some metal complexes have a strong binding affinity for PrP106-126 and a good inhibitory effect against amyloid fibril formation. However, the effects of the metal ligand configuration on peptide binding and aggregation are not well known. To investigate interaction and peptide aggregation between prion neuropeptides and two gold complexes with different ligand configurations ([Au(bpy)Cl2]PF6 and [Au(dien)Cl]Cl2, where bpy is 2,2'-bipyridine and dien is diethylenetriamine), six prion peptides with either a His111-mutated or a Met109/112-mutated residue were used in this study. The selection of the mutant was based on the corresponding neuropeptide from other species. The results showed that the aromatic gold complex [Au(bpy)Cl2]PF6 exhibits better binding affinity and a better inhibitory effect against peptide aggregation than the tridentate complex [Au(dien)Cl]Cl2. For the sequence-specific PrP106-126 and its mutants, His111 plays the most important role in peptide aggregation and binding affinity. Furthermore, Met112 has a greater effect on the binding affinity than Met109. Compared with the mutated short 14 amino acid peptides, the hydrophobic region of PrP106-126 contributes to both binding affinity and self-aggregation behavior. This work will help to understand and develop potential metallodrugs against amyloid disorder.


Subject(s)
Gold/chemistry , Organometallic Compounds/chemistry , Organometallic Compounds/pharmacology , Peptide Fragments/chemistry , Prions/chemistry , Protein Multimerization/drug effects , Amino Acid Sequence , Cell Line, Tumor , Cell Survival/drug effects , Humans , Molecular Sequence Data , Organometallic Compounds/metabolism , Peptide Fragments/metabolism , Peptide Fragments/toxicity , Phenylalanine , Prions/metabolism , Prions/toxicity , Thiazoles/chemistry
18.
Biochimie ; 211: 131-140, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36963557

ABSTRACT

The misfolding and conformational transformation of prion protein (PrP) are crucial to the progression of prion diseases. Screening for available natural inhibitors against prion proteins can contribute to the rational design and development of new anti-prion drugs and therapeutic strategies. The prion neuropeptide, PrP106-126 is commonly used as a model peptide of the abnormal PrPSc, and a number of potential inhibitors were explored against the amyloid fibril formation of PrP106-126. The well-known sesquiterpene lactone, artemisinin, shows diverse biological functions in anti-malarial, anti-cancer and lowering glucose. However, its inhibitory effect on PrP106-126 fibrillation is unclear. In this work, we selected two sesquiterpene lactones, artemisinin (1) and artesunate (2), to explore their roles in PrP106-126 aggregation by a series of physicochemical and biochemical methods. The results demonstrated that 1 and 2 could effectively impede the formation of amyloid fibrils and remodel the preformed fibrils. The binding of the small molecules to PrP106-126 was dominated by electrostatic, hydrophobic and hydrogen bonding interactions. In addition, both compounds exhibited neuroprotective effects by reducing peptide oligomerization. 2 showed better inhibition and regulation on peptide aggregation and cellular viability than 1 due to its specific succinate modification. Our study provides the information of sesquiterpene lactones to prevent PrP fibril formation and other related amyloidosis.


Subject(s)
Artemisinins , Neuropeptides , Prions , Sesquiterpenes , Prions/chemistry , Prions/metabolism , Prions/pharmacology , Amyloid , Sesquiterpenes/pharmacology , Lactones/pharmacology , Peptide Fragments/metabolism
19.
J Cereb Blood Flow Metab ; 43(7): 1042-1059, 2023 07.
Article in English | MEDLINE | ID: mdl-37086081

ABSTRACT

Aging can cause attenuation in the functioning of multiple organs, and blood-brain barrier (BBB) breakdown could promote the occurrence of disorders of the central nervous system during aging. Since inflammation is considered to be an important factor underlying BBB injury during aging, vascular endothelial cell senescence serves as a critical pathological basis for the destruction of BBB integrity. In the current review, we have first introduced the concepts related to aging-induced cognitive deficit and BBB integrity damage. Thereafter, we reviewed the potential relationship between disruption of BBB integrity and cognition deficit and the role of inflammation, vascular endothelial cell senescence, and BBB injury. We have also briefly introduced the function of CREB-regulated transcription co-activator 1 (CRTC1) in cognition and aging-induced CRTC1 changes as well as the critical roles of CRTC1/cyclooxygenase-2 (COX-2) in regulating inflammation, endothelial cell senescence, and BBB injury. Finally, the underlying mechanisms have been summarized and we propose that CRTC1 could be a promising target to delay aging-induced cognitive deficit by protecting the integrity of BBB through promoting inhibition of inflammation-mediated endothelial cell senescence.


Subject(s)
Blood-Brain Barrier , Cognitive Dysfunction , Humans , Blood-Brain Barrier/metabolism , Aging/metabolism , Cognitive Dysfunction/pathology , Inflammation/pathology , Cognition , Transcription Factors/metabolism
20.
Article in English | MEDLINE | ID: mdl-36736944

ABSTRACT

Tobacco smoking is a preventable cause of morbidity and mortality throughout the world. Smoking comes in form of absorption of many compounds, among which nicotine is the main psychoactive component of tobacco and its positive and negative reinforcement effects are proposed to be the key mechanism for the initiation and maintenance of smoking. Growing evidence suggests that the cognitive enhancement effects of nicotine may also contribute to the difficulty of quitting smoking, especially in individuals with psychiatric disorders. In this review, we first introduce the beneficial effect of nicotine on cognition including attention, short-term memory and long-term memory. We next summarize the beneficial effect of nicotine on cognition under pathological conditions, including Alzheimer's disease, Parkinson's disease, Schizophrenia, Stress-induced Anxiety, Depression, and drug-induced memory impairment. The possible mechanism underlying nicotine's effect is also explored. Finally, nicotine's detrimental effect on cognition is discussed, including in the prenatal and adolescent periods, and high-dose nicotine- and withdrawal-induced memory impairment is emphasized. Therefore, nicotine serves as both a friend and foe. Nicotine-derived compounds could be a promising strategy to alleviate neurological disease-associated cognitive deficit, however, due to nicotine's detrimental effect, continued educational programs and public awareness campaigns are needed to reduce tobacco use among pregnant women and smoking should be quitted even if it is e-cigarette, especially for the adolescents.


Subject(s)
Electronic Nicotine Delivery Systems , Tobacco Use Disorder , Pregnancy , Female , Humans , Adolescent , Nicotine/adverse effects , Smoking/psychology , Cognition , Memory Disorders
SELECTION OF CITATIONS
SEARCH DETAIL